Eyegene

Eyegene is dedicated to developing various biologics for the treatment and prevention of age-related diseases to overcome the decline in quality of life caused by aging.The drugs currently under development by Eyegene fall into two main categories: one is a candidate drug for ischemic diseases based on proteomics technology (EGT022), which has been identified through immunological research and can be used to treat diabetic retinopathy, bedsores, wounds, myocardial ischemia, and reperfusion injury; the other is a variety of high-quality adult vaccines.